Cigarette smoking remains one of the most stubborn public health challenges on the planet, a habit that continues to drive cardiovascular disease, respiratory illness, multiple cancers, and a vast burden of preventable death. Yet the scientific machinery aimed at helping people quit is advancing on two fronts at once: the pharmacology of the drugs that dampen nicotine dependence, and the analytical chemistry that guarantees those medicines are pure, potent, and stable. A comprehensive new review published in Discover Industrial Chemistry and Materials by Vijay Arjun Bagul and Sushama Raju Ambadekar of The Institute of Science, Dr. Homi Bhabha State University in Mumbai, weaves these two threads together, offering one of the most integrated portraits yet of the clinical, pharmacological, and analytical dimensions of smoking cessation therapy.
The clinical stakes are enormous. The review opens with the striking evidence from the United Kingdom Million Women Study, which quantified how stopping smoking at roughly 30, 40, or 50 years of age recovers years of life that would otherwise be lost. Against that backdrop, the authors survey the established pharmacopeia of cessation: bupropion, varenicline, nortriptyline, and clonidine. Each acts on a different node of nicotine’s addictive circuitry. Bupropion, an aminoketone antidepressant, inhibits the dopamine and norepinephrine transporters and antagonizes nicotinic acetylcholine receptors, blunting both withdrawal symptoms and relapse risk. Varenicline, a partial agonist at the α4β2 nicotinic receptor, partially mimics the subjective reward of smoking while blocking nicotine’s full activation of the receptor, delivering about 45 percent of nicotine’s maximal effect and attenuating dopamine release induced by the drug itself.
The clinical trial record assembled in the review is remarkable for its breadth. A randomized trial of nortriptyline combined with behavioral counseling achieved a six-month cessation rate of 14 percent versus 3 percent for placebo, with significant reductions in withdrawal symptoms such as anxiety, irritability, and difficulty concentrating. Adding transdermal nicotine to nortriptyline pushed six-month abstinence to 23 percent versus 10 percent with placebo. On the varenicline front, a Chinese randomized controlled trial in smokers with chronic obstructive pulmonary disease reported continuous abstinence of 43.1 percent with varenicline versus 23.5 percent with bupropion among normal nicotine metabolizers. Even vaping cessation is now in scope: a double-blind placebo-controlled trial found biochemically validated continuous abstinence of 40 percent with varenicline plus counseling versus 20 percent with placebo, suggesting the drug’s reach extends beyond traditional cigarettes.
Perhaps the most clinically provocative thread is the nicotine metabolite ratio, or NMR, the ratio of 3′-hydroxycotinine to cotinine that reflects how quickly an individual clears nicotine. In a landmark randomized trial of 1,246 participants, varenicline outperformed the nicotine patch in normal metabolizers, while slow metabolizers benefited equally from the cheaper patch and suffered more varenicline side effects. A 2024 trial in smokers with COPD sharpened the picture further: slow metabolizers experienced more adverse effects from varenicline than bupropion, and no efficacy gap between the two drugs. These findings move the field toward genetically informed, biomarker-guided prescribing, in which a simple metabolic measurement could steer a smoker toward the therapy most likely to work with the fewest harms.
Bupropion’s analytical dossier illustrates the sophistication of modern pharmaceutical quality science. Yeniceli and Dogrukol-Ak developed a thin-layer chromatography method on silica gel plates using an ethanol-chloroform-glacial acetic acid mobile phase, achieving linearity from 200 to 1000 nanograms per band with detection limits near 11 nanograms and precision below 2 percent relative standard deviation. Borges and colleagues built a high-throughput LC-MS/MS assay on a monolithic column that separated bupropion and its metabolites hydroxybupropion and threo-hydrobupropion from human, mouse, and rat plasma in as little as 23 seconds, with isotope-labeled internal standards ensuring sensitivity down to a quarter of a nanogram per milliliter. Meanwhile, a Design of Experiments-driven enantioseparation by HPTLC resolved the enantiomers of bupropion and its active metabolite with resolution factors above 6, underscoring why chirality matters when the two mirror-image forms of a drug can behave differently in the body.
The review also highlights the rise of Analytical Quality by Design, or AQbD, a paradigm that replaces trial-and-error method development with predefined analytical targets, risk assessment, and statistically designed optimization. A striking example is the chaotropic chromatography method developed for bupropion and its five impurities: a Box-Behnken design explored critical method parameters, Monte Carlo simulations defined a design space with at least an 85 percent probability of meeting acceptance criteria, and the validated method was applied directly to commercial Wellbutrin tablets. Similar rigor appears in varenicline analysis, where stability-indicating HPLC methods resolved the drug from forced-degradation products, and where researchers isolated and structurally characterized a previously unknown impurity, 4,6,7,8,9,10-hexahydro-1H-6,10-methanopyrazino[2,3-h]benzazepine-2,3-dione, present at 0.2 percent in tablet samples.
Nortriptyline research adds a delivery-science dimension. Several groups have engineered transdermal patches using hydroxypropyl-methyl-cellulose or chitosan matrices, tuning permeation enhancers such as propylene glycol, ethanol, oleic acid, and polysorbate 80 to push the drug across human skin. Flux values spanning roughly 20 to 256 micrograms per square centimeter per hour mean a patch only 2 to 3.5 centimeters wide could deliver the 25 to 75 milligrams needed daily for cessation therapy, and confocal microscopy confirmed no skin damage. In silico-in vitro extrapolation went further: a one-compartment transport model built from infinite-dose permeation experiments predicted in vivo plasma levels in rats within the therapeutic window, above the 40 nanograms per milliliter threshold associated with cessation benefit. Electrochemical methods, including cathodic adsorptive stripping voltammetry, round out the analytical toolkit with detection limits around 50 nanograms per milliliter.
Clonidine brings a different pharmacological lesson: response is not uniform. The classic 1988 double-blind trial by Glassman and colleagues found clonidine-treated heavy smokers achieved confirmed abstinence at more than twice the rate of placebo, verified by serum cotinine, but the effect was far stronger in women than in men, and a history of major depression predicted relapse regardless of treatment. The drug stimulates presynaptic alpha-2 adrenergic receptors in the brainstem, damping sympathetic outflow and easing irritability, anxiety, and craving. Analytically, clonidine is now measurable by paper spray tandem mass spectrometry, a column-free technique as accurate as conventional HPLC-MS/MS, and by sensitive LC-MS/MS assays in plasma that supported bioequivalence studies of 25-microgram tablets. Forced degradation studies show clonidine is robust under acidic and neutral stress but vulnerable to oxidation, a finding that directly informs storage and formulation decisions.
What unifies this sprawling body of work is the review’s insistence that method validation and sustainability are no longer optional extras. Every method discussed is judged on specificity, accuracy, precision, linearity, range, and robustness under ICH Q2(R2) guidance, and increasingly through green chemistry metrics. The Analytical Eco-Scale scores procedures on reagent hazard, energy use, and waste; AGREE assigns a holistic sustainability score; MoGAPI maps environmental impact across a method’s lifecycle; and the emerging White Analytical Chemistry framework adds red, or analytical-performance, and blue, or practical-applicability, dimensions to the green calculus. A Multi-Color Assessment spanning all four dimensions, the authors argue, is becoming the benchmark for methods fit for routine quality control, pharmacokinetic studies, and bioequivalence testing alike.
The big picture emerging from this synthesis is that quitting smoking is being transformed by data on both sides of the prescription pad. Biomarkers like the nicotine metabolite ratio promise to match patients to varenicline, bupropion, nortriptyline, or patches before the first dose is taken, while validated, stability-indicating, and increasingly green analytical methods guarantee that every tablet delivers exactly what the label claims, even years into its shelf life. The authors point toward combination therapies, innovations in transdermal delivery, gender-specific treatment responses, and high-throughput hybrid analytical platforms as the next frontier. If the clinical and analytical threads continue to braid together at this pace, the humble act of putting out a cigarette for good may soon rest on a foundation of biomarkers, design-of-experiments chromatograms, and sustainability scores, a distinctly twenty-first-century recipe for attacking one of humanity’s oldest addictions.
Subject of Research: Clinical, pharmacological, and analytical review of smoking cessation pharmaceutical drugs
Article Title: A review of clinical, pharmacological and analytical aspects of smoking cessation pharmaceutical drugs
Article References: Bagul, V. A., & Ambadekar, S. R. (2026). A review of clinical, pharmacological and analytical aspects of smoking cessation pharmaceutical drugs. Discover Industrial Chemistry and Materials, 1(1), Article 18. https://doi.org/10.1007/s44508-026-00019-6
Image Credits: AI Generated
DOI: 10.1007/s44508-026-00019-6
Keywords: smoking cessation, bupropion, varenicline, nortriptyline, clonidine, HPLC, LC-MS/MS, nicotine metabolite ratio, forced degradation, impurity profiling, Analytical Quality by Design, green analytical chemistry
Cite Scienmag News
APA MLA Chicago
Bethany Barker. (September 10, 2026). From Brain Receptors to Green Chemistry: The Science Behind Quit-Smoking Drugs. Scienmag. https://scienmag.com/from-brain-receptors-to-green-chemistry-the-science-behind-quit-smoking-drugs/
Bethany Barker. “From Brain Receptors to Green Chemistry: The Science Behind Quit-Smoking Drugs.” Scienmag, 10 September 2026, https://scienmag.com/from-brain-receptors-to-green-chemistry-the-science-behind-quit-smoking-drugs/. Accessed 10 September 2026.
Bethany Barker. “From Brain Receptors to Green Chemistry: The Science Behind Quit-Smoking Drugs.” Scienmag. September 10, 2026. https://scienmag.com/from-brain-receptors-to-green-chemistry-the-science-behind-quit-smoking-drugs/
Copy citation Download RIS
Tags: advancements in smoking cessation drug stability and potencyanalytical chemistry in drug developmentAnalytical Quality by Designbupropionclinical trials for smoking cessation drugsclonidineforced degradationgreen analytical chemistrygreen chemistry in pharmaceutical manufacturingHPLCimpurity profilingintegrated approach to smoking cessation therapyLC-MS/MSnicotine addiction neurobiologynicotine dependence treatmentnicotine metabolite rationortriptylinepharmacological mechanisms of bupropion and vareniclinepublic health impact of quitting smokingquality control of smoking cessation medicationsrole of brain receptors in nicotine addictionsmoking cessationsmoking cessation pharmacologyvarenicline
